Yelin Lapidot Holdings Management’s Harmony Biosciences HRMY Stock Holding History

Yelin Lapidot Holdings Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Hold	35,887	–	–	0.25%	56
2026 Q1	$1.01M	Hold	35,887	–	–	0.21%	60
2025 Q4	$1.34M	Hold	35,887	–	–	0.27%	56
2025 Q3	$989K	Hold	35,887	–	–	0.21%	59
2025 Q2	$1.13M	Hold	35,887	–	–	0.21%	61
2025 Q1	$1.19M	Hold	35,887	–	–	0.23%	60
2024 Q4	$1.23M	Sell	35,887 -2,018	-5%	-$69.3K	0.22%	57
2024 Q3	$1.52M	Hold	37,905	–	–	0.25%	52
2024 Q2	$1.14M	Hold	37,905	–	–	0.2%	56
2024 Q1	$1.27M	Hold	37,905	–	–	0.26%	57
2023 Q4	$1.22M	Hold	37,905	–	–	0.3%	54
2023 Q3	$1.3M	Buy	+37,905	New	+$1.32M	0.32%	51

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Yelin Lapidot Holdings Management's HRMY Position: Q2 2026 in Review

Yelin Lapidot Holdings Management held its Harmony Biosciences (HRMY) position steady in Q2 2026 at 35,887 shares worth $1.31M. The position accounts for 0.25% of the portfolio, ranked #56.

Yelin Lapidot Holdings Management first reported a position in HRMY in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.52M in Q3 2024. 131 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Yelin Lapidot Holdings Management held 35,887 shares of Harmony Biosciences worth $1.31M as of Q2 2026.
Yelin Lapidot Holdings Management left its Harmony Biosciences share count unchanged in Q2 2026.
Harmony Biosciences made up 0.25% of Yelin Lapidot Holdings Management's portfolio in Q2 2026, its #56 holding.
Yelin Lapidot Holdings Management first reported a position in Harmony Biosciences in Q3 2023 and has held it in 12 quarters since.
Yelin Lapidot Holdings Management's Harmony Biosciences position peaked at $1.52M in Q3 2024.
131 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Yelin Lapidot Holdings Management's 13F filing for Q2 2026, filed 3 Aug 2026.